Abstract
Abstract
Although current antiemetic agents, either singularly or in combination, have had substantial positive effects on controlling chemotherapy-induced nausea and vomiting (CINV), there are still concerns regarding how well advanced practitioners can effectively manage delayed nausea and vomiting with the current array of modalities. A review of antiemetic development and research in the past has formed the basis for current standard-of-care antiemetics. The same will hold true for new antiemetics and improvements in antiemetic and other therapy guidelines for CINV. New agents are undergoing study, and other ways to view “success” and “efficacy” in quantitative and qualitative studies for CINV are being considered.
